

QUARTERLY
DISCLOSURE STATEMENT

Current through
March 31, 2012

Nouveau Life Pharmaceuticals, Inc.
Corporate office
401 E. Las Olas Blvd
Ft. Lauderdale, Florida 33301

Cusip No
66979K 103

Tax ID
45-2221635

Trading Symbol
NOUV

Item 1 Exact name of the issuer and the address of its principal executive offices.

Nouveau Life Pharmaceuticals, Inc. formerly known as Hybrid Fuels, Inc.
401 E. Las Olas Blvd, Ft. Lauderdale, Florida 33301

Item 2 Shares outstanding.

Period end date	-----	March 31, 2012
Common shares authorized	-----	900,000,000
Common shares outstanding	-----	899,999,733
Freely tradable shares	-----	147,462,475
Total number of shareholders of record	-----	266

Period end date	-----	December 31, 2011
Common shares authorized	-----	900,000,000
Common shares outstanding	-----	899,999,733
Freely tradable shares	-----	147,462,475
Total number of shareholders of record	-----	266

Period end date	-----	September 30, 2011
Common shares authorized	-----	190,000,000
Common shares outstanding	-----	157,999,733
Preferred shares authorized	-----	10,000,000
Preferred shares issued	-----	10,000,000
Free trading shares (public float)	-----	22,462,475
Total number of shareholders of record	-----	262

Item 3 Interim financial statements.

The financial statements and notes have been uploaded on the Company's OTC Markets website under the tab marked Financials. The statements include the following information.

- 1) Balance sheet;
- 2) Statement of income;
- 3) Shares Outstanding

Item 4 Management's discussion and analysis or plan of operation.

There are no known events likely to have a material impact on the Company's liquidity. However, the Company has meager cash reserves and access to a limited line of credit that may not provide the Company with the necessary funds to address its liquidity requirements. Nouveau Life is a relatively new business venture and has no history of earnings or profit and there is no assurance that it will operate profitably in the future. As such, there is no assurance that it will provide a return on investment.

The company has operating losses from the initial implementation of its operations, and it faces unforeseen costs, expenses, problems and difficulties that could easily prevent it from ever being profitable. The company is in the early stages of development and could fail before implementing its business plan.

Item 5 Legal proceedings.

No legal proceedings are threatened or pending against the Company or any of its officers or directors; none of the Company's officers, directors or affiliates have material interest in actions that are adverse to the Company's interests

Item 6 Defaults upon senior securities.

The Company has had no material default of any financial or contractual instruments

Item 7 Other information.

On May 9, 2012 Mr. Ramiro Cadena resigned and Ms. Melissa Walker was appointed as the Company's new CEO and President.

Item 8 Exhibits.

As of this date, the company has entered into no contracts or leases upon which the company's business is substantially dependent. The amended, restated articles of Incorporation, by laws, unaudited financial statements, and other relevant documents are made available on this website

Item 9 Certifications.

I, Melissa Walker, certify that:

I have reviewed this annual disclosure statement of Nouveau Life Pharmaceuticals, Inc, and based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this disclosure statement, and based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Date: March 31, 2012

\S\Melissa Walker,
President